专利分类建议生成

以下分类建议以国际专利分类（IPC）为主，并辅以在必要时可采用的CPC参考。鉴于案涉主题为“碳化硅功率模块封装散热结构及其可靠性测试方案”，本案涉及两类技术要点：一是功率模块封装结构中的散热/热管理；二是针对封装模块的可靠性测试方法与装置。根据IPC分类原则，应分别就不同技术方面赋予相应分类，专门条目优先于一般条目，主分类以反映权利要求的核心技术特征为准。

一、分类建议总览

1. 封装散热结构（主分类，视独立权利要求而定）

• IPC 主类：
  • H01L 23/34（半导体器件的热管理/散热布置；用于将热量从半导体本体导出至外部散热体的结构）
  • H01L 25/00（由多个半导体或其他固态器件组成的组件；如功率模块整体封装结构涉及多芯片、DBC/IMS/基板-底板等堆叠与互连）
• IPC 可能的并列/补充分类（依从属特征具体增列）：
  • H05K 7/20（电气装置的冷却布置；若权利要求强调与外部冷却构件、机壳、冷板的配合结构而非器件内部封装细节）
• CPC 参考（如采用CPC可更精细标引）：
  • H01L 23/373（冷却/散热布置，包括散热片、热扩展片等）
  • H01L 23/398（热扩展/热扩散构件的特定布置）
  • H01L 23/473（采用流体冷却之冷却通道/冷板布置；若权利要求涉及液冷/两相冷却等）
  • H01L 25/071、H01L 25/075（多器件组件中采用绝缘基板、DBC/AMB等模块化封装堆叠与互连的细分；据权利要求具体结构选配）

2. 可靠性测试方案（并列主分类或补充分类，视是否为独立发明点）

• IPC 主类：
  • G01R 31/26（用于测试电性质的装置或方法；电子电路或器件的测试）
  • G01R 31/28（半导体器件的测试；如权利要求明确针对功率半导体模块之电应力、老化、失效判据与在线监测）
• CPC 参考（如采用CPC）：
  • G01R 31/26（总项）
  • G01R 31/28（半导体器件测试；可覆盖功率器件的通断特性、RDS(on)、VCE(sat) 等监测与应力加速） 注：若测试方案以环境应力试验为核心（如温度循环、湿热偏置、功率循环），仍以G01R 31/26、31/28为主；仅当权利要求本质上为材料/热分析仪器方法时，方考虑G01N热分析类目。

二、分类理由与适用性分析

• 关于H01L 23/34：本案“封装散热结构”的技术要点在于半导体器件封装内部或与封装直接相关的热通路设计，例如芯片-焊料/烧结层-金属化陶瓷基板-底板-散热件的热路径优化、热扩展片、界面材料（TIM）布置、应力与热失配缓解等。该类特征属于半导体封装范畴中的热管理专门条目，宜作为封装结构的主分类。
• 关于H01L 25/00：若权利要求指向功率模块层级的系统化封装（多芯片、并联/串联连接、母排、DBC/AMB 基板、钎焊/银烧结堆叠、绝缘与导热兼顾），则除热管理外，其“多器件组件”属性亦应得到反映，H01L 25/00适合作为并列主分类或补充分类。
• 关于H05K 7/20：当权利要求将创新点落在外部冷却装置或机电一体化的冷却结构（如机壳/散热器/风道/冷板）而与封装内部结构的界定较弱时，可用作补充分类。但若创新本质属于半导体封装热管理，应以H01L 23/34优先。
• 关于G01R 31/26与31/28：可靠性测试方案通常涵盖电应力加速（如HTRB、HTGB）、温度/湿热偏置、功率循环与在线参数监测（导通电阻、阈值漂移、结温估算等）。其技术性质为“对半导体器件或模块进行电学测试与失效判断的试验方法/装置”，故归入G01R 31/26及其半导体细分31/28。若试验重在电学与环境应力的耦合，不影响以G01R为主的归类结论。

三、具体适用与操作建议

• 若独立权利要求以封装热管理结构为核心：建议主分类设为H01L 23/34；视模块级结构特征增列H01L 25/00；如涉及外部冷板/壳体之构造改进，再增列H05K 7/20。采用CPC时，按是否包含热扩展片、液冷通道等，分别标引H01L 23/373、H01L 23/398、H01L 23/473及与模块基板相关的H01L 25/071、H01L 25/075。
• 若另有独立权利要求专门覆盖可靠性测试方案：建议为该独立方案单独设主分类G01R 31/26，并增列G01R 31/28以体现半导体器件/模块的对象属性。
• 不建议以材料学本体（如“碳化硅材料”）条目作为主分类，因本案的权利要求焦点为封装与测试而非器件材料本身；如说明书大量涉及材料表征而形成从属技术要点，可在检索阶段作为辅助检索线索，而非分类优先项。

四、合规性与检索影响

• 以上建议符合IPC分类原则中“专门优先于一般”“多方面技术分别分类”的规则。封装结构与测试方法分别赋类，有助于检索覆盖EPO/USPTO/CNIPA关于功率模块封装与可靠性领域的主流先前技术。
• 在CPC环境下，适当采用更精细的小组能够提高检索精度，尤其是对液冷模块、热扩展片、DBC/AMB堆叠、界面材料布局等具体特征的定位。

结论

• 封装散热结构（主）：H01L 23/34；并列/补充：H01L 25/00；情形需要时增列H05K 7/20；CPC参考：H01L 23/373、H01L 23/398、H01L 23/473、H01L 25/071、H01L 25/075。
• 可靠性测试方案（主或并列主）：G01R 31/26；补充：G01R 31/28。

上述分类配置可在权利要求最终定稿后按具体技术特征微调，以确保主分类准确反映发明的技术实质。

Proposed patent classification (subject to final allocation under the competent office’s classification practice)

1. Primary classification (invention information)

• IPC: C12Q 1/68 — Measuring or testing processes involving nucleic acids (e.g., detection of DNA/RNA sequences, including guide-RNA-mediated detection). Rationale: The claimed programmable CRISPR assay detects tumor biomarkers through nucleic-acid-based recognition and nuclease activity; the essence of the invention lies in nucleic acid testing.

2. Additional classifications (secondary/ancillary aspects)

• IPC: G01N 27/00 — Investigating or analyzing materials by the use of electrochemical means. Rationale: The claimed biosensor employs an electrochemical transducer/readout; the electroanalytical configuration is a material technical feature relevant for search and examination.

3. CPC refinements (where CPC is applied)

• CPC: C12Q 1/68 (and its appropriate CRISPR-focused subgroup under this main group, as available in the current CPC release). Rationale: CPC provides more granular breakdowns under C12Q 1/68 for nuclease-mediated (including CRISPR/Cas) nucleic-acid assays. The precise subgroup selection depends on the specific claim features (e.g., collateral cleavage by Cas12/Cas13, target amplification, guide design, reporter architecture).
• CPC indexing: C12N 2310/20 — CRISPR-associated systems (indexing scheme). Rationale: Where the claims explicitly recite CRISPR/Cas effectors, this indexing tag is appropriate to capture the gene-editing nuclease platform as a detection engine, improving search precision.
• CPC: G01N 27/00 (appropriate subgroup for electrochemical biosensors immobilizing biological recognition elements on electrodes). Rationale: To reflect the electrochemical transduction modality and electrode-functionalization features. The exact subgroup is selected based on claim specifics (e.g., nature of electrode, immobilized nucleic-acid probes or Cas proteins, impedance vs voltammetric readout).

4. Conditional cross-classification depending on the claim set

• If the claimed analyte is a nucleic-acid tumor biomarker (e.g., ctDNA, miRNA, fusion transcripts): retain C12Q 1/68 as the primary symbol; refine within CPC under the nucleic-acid/CRISPR subgroups.
• If the claimed analyte is a protein tumor biomarker detected via a CRISPR-triggered nucleic-acid reporter (e.g., aptamer-to-DNA circuit that activates Cas cleavage): maintain C12Q 1/68 (nucleic-acid testing) as primary because the measurable reaction and readout are nucleic-acid based; add G01N 27/00 for the electrochemical modality. Where the claims emphasize the clinical use for cancer diagnostics (in vitro), an additional G01N 33 group relating to analysis of biological material may be included per office practice; however, this should not displace C12Q 1/68 as the principal classification.
• If the claims include detailed electrode fabrication, nanomaterials, or specific electroanalytical methods (e.g., differential pulse voltammetry, impedance spectroscopy), assign the corresponding G01N 27 subgroup(s) for the electrochemical technique used.
• If the claims recite particular Cas effectors (e.g., Cas12a, Cas13a) or specific guide RNA engineering, apply the available CPC CRISPR-focused subgroups under C12Q 1/68 and add the C12N 2310/20 indexing tag.

Classification rationale and selection principles

• Under IPC and CPC practice, inventions directed to in vitro detection via nucleic-acid recognition are primarily classified in C12Q 1/68. Electrochemical readout does not displace the nucleic-acid testing core but warrants additional classification in G01N 27.
• CPC affords finer granularity for both CRISPR-based diagnostics (subgroups under C12Q 1/68) and electrochemical biosensing (subgroups under G01N 27). Final subgroup assignment should follow the claim-dominant features: (i) target class (DNA/RNA), (ii) nuclease mechanism (cis vs trans cleavage), (iii) transduction method (amperometric, potentiometric, impedimetric), and (iv) electrode configuration/immobilization chemistry.
• Where claims present distinct statutory categories (method of detection; sensor device; kit), each may receive parallel classification: method in C12Q 1/68; device in G01N 27 (with C12Q cross-reference if appropriate); and kit in C12Q 1/68, with CPC indexing for CRISPR.

Summary (concise symbols)

• IPC (primary): C12Q 1/68.
• IPC (additional): G01N 27/00.
• CPC: C12Q 1/68 (appropriate CRISPR-focused subgroup per claim content); G01N 27/00 (appropriate electrochemical biosensor subgroup); indexing C12N 2310/20 for CRISPR systems.

Note: The exact CPC subgroup designations should be finalized against the most current CPC schedule and the definitive claim language (e.g., identification of the Cas enzyme, guide design, collateral cleavage reporters, and specified electrochemical technique). This approach accords with WIPO IPC and CPC classification principles prioritizing the technical features that provide the essential character of the claimed invention.